SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
APMD

Apnimed, Inc. (NASDAQ:APMD)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$16.09-$1.16 (-6.70%)
 
Market cap
$670M
Insider Score
Listed since
Jul 29, 2026
Market Cap$669.84M+0.6%
Revenue (ttm)n/a
Net Incomen/a
EPSn/a
Shares Out41.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume248,586
Open$17.08
Previous Close$17.25
Day's Range$15.95 - $17.73
52-Week Range$13.88 - $35.29
Beta7.95
Analystsn/a
Price Target$60.00(+272.90%)
Earnings Daten/a

About APMD

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Address
39 John F. Kennedy Street, Cambridge, MA, 02138, US
Market Cap
670 million
Employees
81
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$5.20M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

When insiders bought and sold

1 year · open-market trades only
Closing Price Purchase Sale
$13.03$23.60$34.18AugOct
1 Day
-6.70%
5 Days
+0.25%
1 Month
-13.17%
6 Months
+0.56%
1 Year
+0.56%

$APMD stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in APMD holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by APMD's directors and management

Net Shares Purchased by Insiders−400k−200k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

APMD Estimated quarterly lobbying spending

Source: U.S. Senate LDA

APMD Revenue by Segment

$19.86MTotal
Stock-based compensation$6.27M31.58%
Commercial marketing$5.16M25.95%
Medical affairs$2.71M13.64%
Oxnimbi$2.52M12.67%
Revenue - related party$2.48M12.48%
Change in fair value of revenue interest liability$260.00K1.31%
Cost of services - related party$245.00K1.23%
Connected wearables$219.00K1.10%
Other projects$7.00K0.04%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New APMD patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to APMD from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in APMD

IWMiShares Russell 2000 ETF$5.59M
VTIVanguard Morningstar Total Stock Market ETF$5.15M
VXFVanguard Extended Market ETF$2.22M
IWOiShares Russell 2000 Growth ETF$1.19M
VTWOVanguard Russell 2000 ETF$1.19M
SCHASchwab U.S. Small-Cap ETF$1.05M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from APMD’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
24.41
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
2
Sells
0
Buy Value
$5.20M
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IBRNiShares Neuroscience and Healthcare ETF0.97%
JDOCJPMorgan Healthcare Leaders ETF0.21%
PJSMPGIM Jennison Small-Mid Cap Core Equity ETF0.10%
IWCiShares Micro-Cap ETF0.05%

Weight is the stock’s share of each fund’s holdings.